Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral load, combined 74% Improvement Relative Risk Viral load, E 96% Viral load, S 44% c19early.org/p Natto et al. Povidone-Iodine for COVID-19 RCT EARLY Does povidone-iodine reduce short-term viral load for COVID-19? RCT 24 patients in Saudi Arabia Trial compares with saline, results vs. placebo may differ Improved viral load with povidone-iodine (not stat. sig., p=0.27) Natto et al., Medicine, doi:10.1097/MD.0000000000028925 Favors povidone-iodine Favors saline
The short-term effect of different chlorhexidine forms versus povidone iodine mouth rinse in minimizing the oral SARS-CoV-2 viral load: An open label randomized controlled clinical trial study
Natto et al., Medicine, doi:10.1097/MD.0000000000028925
Natto et al., The short-term effect of different chlorhexidine forms versus povidone iodine mouth rinse in minimizing the.., Medicine, doi:10.1097/MD.0000000000028925
Jul 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
60 patient RCT comparing chlorhexidine, PVP-I, and saline in Saudi Arabia with a single mouth rinse treatment and PCR testing 5 minutes later, showing statistically significant improvement in Ct value for PVP-I. PVP-I showed greater improvement than saline, without statistical significance.
risk of viral load, 74.0% lower, RR 0.26, p = 0.27, treatment 12, control 12, relative improvement in Ct value, both genes combined.
risk of viral load, 96.2% lower, RR 0.04, p = 0.12, treatment mean 4.43 (±4.78) n=12, control mean 0.17 (±7.67) n=12, relative improvement in Ct value, E gene.
risk of viral load, 44.4% lower, RR 0.56, p = 0.60, treatment mean 3.33 (±5.6) n=12, control mean 1.85 (±7.68) n=12, relative improvement in Ct value, S gene.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Natto et al., 29 Jul 2022, Randomized Controlled Trial, Saudi Arabia, peer-reviewed, 7 authors, this trial compares with another treatment - results may be better when compared to placebo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Abstract: Medicine ® Clinical Trial/Experimental Study The short-term effect of different chlorhexidine forms versus povidone iodine mouth rinse in minimizing the oral SARS-CoV-2 viral load An open label randomized controlled clinical trial study Zuhair S. Natto, DrPHa,* , Muhammed A. Bakhrebah, PhDb, Marwah Afeef, MScc, Samiah Al-Harbi, BAd, Majed S. Nassar, PhDb, Abdulkarim F. Alhetheel, PhDe,f, Heba Ashi, PhDa Abstract Several investigations evaluated the possibility of different types of mouth wash rinse in minimizing the SARS-CoV-2 load. However, results still controversial. The study aim is to assess the short-term efficiency of several over-the-counter mouth rinses and lozenges in minimizing the salivary viral load for SARS-CoV-2 in patients with confirmed COVID-19 in comparison to saline. This is a randomized controlled clinical trial with 4 arms. The recruited cases were randomized using a simple randomization technique and were assigned to chlorhexidine digluconate mouth rinse (CHX mouth rinse), 2 mg of chlorhexidine digluconate lozenges (CHX lozenges), povidone iodine mouth rinse (PVP-I mouth rinse) or saline as a control group. Saliva were collected from all study subjects by passive drool technique at two time points. First, prior to intervention with mouth rinse or the lozenges, the baseline saliva sample was collected. Second saliva samples were collected immediately after the mouth rinse. Real time PCR was conducted and the value threshold cycle (Ct) for each sample was recorded. Majority of the participants had an education level of high school or less (60%), were married (68.3), males (58.3%), and nonsmokers (58.5%). No statistically significant differences between groups at the two times test (P > .05). However, a significant decrease of salivary viral load in all four groups combined (P-value for E genes = .027, and for S genes = .006), and in PVP-I mouth rinse specifically (P = .003 and P = .045, respectively). Povidone iodine mouth rinse showed a potential influence on the reduction of the viral load on a short-term basis. However, longer-term studies of the effect of these products should be conducted. Abbreviations: CHX mouth rinse = digluconate mouth rinse, CHX lozenges = chlorhexidine digluconate lozenges, PVP-I mouth rinse = povidone iodine mouth rinse, Ct = threshold cycle, SARS-CoV-2 = Severe Acute Respiratory Syndrome Coronavirus 2, KFGH = King Fahad General Hospital, RT-PCR = Real-time polymerase chain reaction. Keywords: COVID-19, SARS-CoV-2, mouth rinse, chlorhexidine digluconate, povidone iodine especially given the new variants, and the chances of its transmission with asymptomatic patients is still very high.[7] The SARS-CoV-2 incubation period has been reported to range between 1 and 14 days, with most evidence suggested it to be 3 to 7 days.[5] Therefore, there is evidence indicating the possibility of infection spreading when patients were unaware about their infection status and asymptomatic.[8,9] Current evidence proved saliva can act as a SARS-CoV-2 reservoir.[9] Several reports found that the virus is transmitted through aerosols, which pose a significant possibility for transmission risk of the infection in dental clinics.[5,7] So, it is required to decrease this potential risk in dental offices, by minimizing the salivary SARS-CoV-2 load, if possible,
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit